Cholangiocarcinoma classification: current approach, relevance and challenges

Benjamin Goeppert^{1

2}, Yoh Zen³, Juan Valle⁴, David Klimstra⁵, Vikram Deshpande⁶

Affiliations

¹ Institute of Pathology, Regionale Kliniken Holding RKH GmbH, Ludwigsburg, Germany.
² Institute of Pathology, Heidelberg University, Heidelberg, Germany.
³ Liver Institute, King's College Hospital, London, UK.
⁴ Research Department, Cholangiocarcinoma Foundation, Herriman, Utah, USA.
⁵ Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
⁶ Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA eic.jcp.deshpande@gmail.com.

Editorial

Benjamin Goeppert et al. J Clin Pathol. 2025.

. 2025 Apr 17;78(5):298-299.

doi: 10.1136/jcp-2024-209708.

Benjamin Goeppert^{1

2}, Yoh Zen³, Juan Valle⁴, David Klimstra⁵, Vikram Deshpande⁶

¹ Institute of Pathology, Regionale Kliniken Holding RKH GmbH, Ludwigsburg, Germany.
² Institute of Pathology, Heidelberg University, Heidelberg, Germany.
³ Liver Institute, King's College Hospital, London, UK.
⁴ Research Department, Cholangiocarcinoma Foundation, Herriman, Utah, USA.
⁵ Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
⁶ Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA eic.jcp.deshpande@gmail.com.

No abstract available

Keywords: Biomarkers, Tumor; CHOLANGIOCARCINOMA; NEOPLASMS.

Conflict of interest statement

Competing interests: VD is the Editor in Chief of the Journal of Clinical Pathology. YZ is an Associated Editor of the Journal of Clinical Pathology.